Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis

Circulation

Volumn 106, Issue 13, 2002, Pages 1664-1671

  Cid, Maria C ^a,c   Hernández Rodríguez, José ^a   Esteban, María José ^a   Cebrián, Mireia ^a   Gho, Yong Song ^b   Font, Carme ^a   Urbano Márquez, Alvaro ^a   Grau, Josep M ^a   Kleinman, Hynda K ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Angiogenesis; Inflammation; Vasculature

Indexed keywords

ACUTE PHASE RESPONSE; ADULT; AGED; ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CAPILLARY; CELL GROWTH; CHICK EMBRYO; CHORIOALLANTOIS; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; FEMALE; GIANT CELL ARTERITIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIA; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TEMPORAL ARTERY; UMBILICAL VEIN;

ACUTE-PHASE REACTION; AGED; AGED, 80 AND OVER; ANIMALS; BIOLOGICAL ASSAY; BIOPSY; BLOOD PROTEINS; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; CHICK EMBRYO; CHORION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; ISCHEMIA; LECTINS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PLANT LECTINS; PROSPECTIVE STUDIES; REFERENCE VALUES; TEMPORAL ARTERIES; TEMPORAL ARTERITIS; VASA VASORUM;

EID: 0037167646     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000030185.67510.C0     Document Type: Article

References (35)

1. Hunder GG. Giant-cell arteritis and polymyalgia rheumatica. Med Clin North Am. 1997;81:195-219.
2. Cid MC, Hernández-Rodríguez J, Grau JM. Vascular manifestations in giant-cell arteritis. In: Asherson RA, Cervera R, eds. Vascular Manifestations of Systemic Autoimmune Diseases. Boca Raton, Fla: CRC Press; 2001:237-249.
3. Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 1998;41:26-32.
4. Klein RG, Hunder GG. Stanson AW, et al. Large artery involvement in giant-cell (temporal) arteritis. Ann Intern Med. 1975:83:806-812.
5. Font C. Cid MC, Coll-Vinent B, et al. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol. 1997;36:251-254.
6. González-Gay MA, García-Porrúa C, Llorca J, et al. Visual manifestations of giant-cell arteritis: trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79:283-292.
7. Carmeliet P. Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
8. Szekanecz A, Szegedi G, Koch AE. Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. J Invest Med. 1998;46:27-41.
9. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med. 1997;3:158-1263.
10. 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97:1114-1123.
11. Charney R. Cohen M. The role of the coronary collateral circulation in limiting myocardial ischemia and infarct size. Am Heart J. 1993;126:937-945.
12. 165 as sole therapy for myocardial ischemia. Circulation. 1998;98:2800-2804.
13. Cid MC. New developments in the pathogenesis of systemic vasculitis. Curr Opin Rheumatol. 1996:8:1-11.
14. Cid MC, Font C, Coll-Vinent B, et al. Large vessel vasculitides. Curr Opin Rheumatol. 1998:10:18-28.
15. Cid MC, Cebrián M, Font C, et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant-cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte/endothelial cell interactions. Arthritis Rheum. 2000;43:184-194.
16. Cid MC, Grau JM, Casademont J, et al. Immunohistochemical characterization of inflammatory cells and immunologic activation markers in muscle and nerve biopsies from patients with systemic polyarteritis nodosa. Arthritis Rheum. 1994;37:1055-1061.
17. Coll-Vinent B, Cebrian M, Cid MC, et al. Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis Rheum. 1998;41:435-444.
18. Cid MC, Hernández-Rodríguez J, Robert J, et al. Interferon-alpha may exacerbate cryoglobulinemia-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic activity. Arthritis Rheum. 1999;42:1051-1055.
19. Cid MC, Grant DS, Hoffman GS, et al. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest. 1993;91:977-985.
20. Hernández-Rodríguez J, García-Martínez A, Casademont J, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements an longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum. 2002;47:29-35.
21. Kleinman HK, MC Cid. Preparation of endothelial cells. In: Bonifacino JS, Dasso M, Harford JB, et al, eds. Current Protocols in Cell Biology. New York: John Wiley & Sons, Inc; 1998:1-4.
22. Kaiser M, Younge B, Björnsson J, et al. Formation of new vasa vasorum in vasculitis: production of angiogenic cytokines by multinucleated giant-cells. Am J Pathol. 1999;155:765-774.
23. Grant DS, Tashiro KI, Seguí-Real B, et al. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell. 1989;58:933-943.
24. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J. 1992;6:2591-2599.
25. Epstein SE, Kornowski R, Fuchs S, et al. Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation. 2001;104:115-119.
26. Esteban MJ, Font C, Hernández-Rodríguez J, et al. Small-vessel vasculitis surrounding a spared temporal artery: clinical and pathologic findings in a series of twenty-eight patients. Arthritis Rheum. 2001;44:1387-1395.
27. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-247.
28. Salcedo R, Young HA, Ponce ML, et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol. 2001;166:7571-7578.
29. Ponce ML, Nomizu M, Kleinman HK. An angiogenic laminin site and its antagonist bind through the αvβ3 and α5β1 integrins. FASEB J. 2001;15:1389-1397.
30. Salcedo R, Ponce ML, Young HA, et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood. 2000;96:34-40.
31. Gho YS, Kleinamn HK, Sosne G. Angiogenic activity of soluble intercellular adhesion molecule-1. Cancer Res. 1999;59:5128 5132.
32. Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant-cell arteritis. Ann Intern Med. 1994;121:484-491.
33. Weyand CM, Goronzy JJ. Arterial wall injury in giant-cell arteritis. Arthritis Rheum. 1999;42:844-853.
34. Coll-Vinent B, Vilardell C, Font C, et al. Circulating soluble adhesion molecules in patients with giant-cell arteritis: correlation between soluble intercellular adhesion molecule-I (SCAM-1) and disease activity. Ann Rheum Dis. 1999;58:189-192.
35. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.